The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

BACKGROUND: The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is unknown. OBJECTIVES: To determine the association between progression of metastatic BRAF V600 mutated melanoma and (1) dose reductions of vemurafenib and (2) simultaneous use of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Target Oncol
Hauptverfasser: Knapen, Lotte M., Koornstra, Rutger H. T., Driessen, Johanna H. M., van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R., Burger, David M., de Vries, Frank, van Erp, Nielka P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2018
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6004282/
https://ncbi.nlm.nih.gov/pubmed/29644577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-018-0564-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge